These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 8035098)

  • 1. Recent progress on the biologic and clinical significance of advanced glycosylation end products.
    Vlassara H
    J Lab Clin Med; 1994 Jul; 124(1):19-30. PubMed ID: 8035098
    [No Abstract]   [Full Text] [Related]  

  • 2. Advanced glycation end products: sparking the development of diabetic vascular injury.
    Goldin A; Beckman JA; Schmidt AM; Creager MA
    Circulation; 2006 Aug; 114(6):597-605. PubMed ID: 16894049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro advanced glycation end product formation in rat tail tendon fibers: influence of aminoguanidine.
    Troncoso IA; Esteban MM; Ruiz MA; Flórez L; Barneo L
    Transplant Proc; 1995 Dec; 27(6):3345-6. PubMed ID: 8539985
    [No Abstract]   [Full Text] [Related]  

  • 4. Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end-products: comparison with aminoguanidine.
    Booth AA; Khalifah RG; Hudson BG
    Biochem Biophys Res Commun; 1996 Mar; 220(1):113-9. PubMed ID: 8602828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advanced glycation end-products in diabetes mellitus, with particular reference to angiopathy.
    Chiarelli F; Mansour M; Verrotti A
    Diabetes Nutr Metab; 2000 Aug; 13(4):192-9. PubMed ID: 10961486
    [No Abstract]   [Full Text] [Related]  

  • 6. [Progress on the drug therapy for diabetic microangiopathies: AGE inhibitors].
    Yamagishi S; Imaizumi T
    Nihon Rinsho; 2005 Jun; 63 Suppl 6():136-8. PubMed ID: 15999696
    [No Abstract]   [Full Text] [Related]  

  • 7. Alterations in venous endothelial cell and smooth muscle cell relaxation induced by high glucose concentrations can be prevented by aminoguanidine.
    Davies MG; Hagen PO
    J Surg Res; 1996 Jul; 63(2):474-9. PubMed ID: 8661245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AGE-RAGE interactions: sticky sugar kills.
    Chee YC
    Singapore Med J; 2001 Apr; 42(4):145-7. PubMed ID: 11465312
    [No Abstract]   [Full Text] [Related]  

  • 9. Gene expression of receptor for advanced glycosylation end products and its modulation by aminoguanidine in diabetic kidney tissue.
    Huang Y; Lin S; Zhou J
    Chin Med J (Engl); 1998 Aug; 111(8):698-704. PubMed ID: 11245022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Advanced glycosylation end products or glycotoxins: under-evaluated components of diet?].
    Wautier JL
    Rev Prat; 2001 Sep; 51(13):1397-9. PubMed ID: 11601066
    [No Abstract]   [Full Text] [Related]  

  • 11. Advanced glycosylated end products and hyperglycemia in the pathogenesis of diabetic complications.
    Friedman EA
    Diabetes Care; 1999 Mar; 22 Suppl 2():B65-71. PubMed ID: 10097902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advanced glycation end products upregulate angiogenic and pro-inflammatory cytokine production in human monocyte/macrophages.
    Pertyńska-Marczewska M; Kiriakidis S; Wait R; Beech J; Feldmann M; Paleolog EM
    Cytokine; 2004 Oct; 28(1):35-47. PubMed ID: 15341924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pathological implications of protein glycation.
    Brownlee M
    Clin Invest Med; 1995 Aug; 18(4):275-81. PubMed ID: 8549013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of benzoimidazole and guanidine hydrochloride on protein biosynthesis in chick fibroblast cultures].
    Denys A; Kedziora J
    Med Dosw Mikrobiol; 1971; 23(1):77-81. PubMed ID: 5103920
    [No Abstract]   [Full Text] [Related]  

  • 15. Vascular endothelial growth factor receptor-2 and low affinity VEGF binding sites on human glomerular endothelial cells: Biological effects and advanced glycosilation end products modulation.
    Pala L; Cresci B; Manuelli C; Maggi E; Yamaguchi YF; Cappugi P; Rotella CM; Giannini S
    Microvasc Res; 2005 Nov; 70(3):179-88. PubMed ID: 16271941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [How can diabetic retinopathy be therapeutically modified? Advanced glycosylation end products (AGEs) and hyperglycemic memory].
    Hammes HP
    Fortschr Med; 1997 Mar; 115(7):53-4. PubMed ID: 9173024
    [No Abstract]   [Full Text] [Related]  

  • 17. Pathogenic role of advanced glycosylation end products in diabetic nephropathy.
    Lee HB; Cha MK; Song KI; KIm JH; Lee EY; Kim SI; Kim J; Yoo MH
    Kidney Int Suppl; 1997 Sep; 60():S60-5. PubMed ID: 9285904
    [No Abstract]   [Full Text] [Related]  

  • 18. Aminoguanidine and the prevention of leukocyte dysfunction in diabetes mellitus: a direct vital microscopic study.
    Sannomiya P; Oliveira MA; Fortes ZB
    Br J Pharmacol; 1997 Nov; 122(5):894-8. PubMed ID: 9384505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of advanced glycosylation end products on activity of protein kinase C in human peripheral blood mononuclear cells.
    Tong J; Liu N
    Chin Med J (Engl); 2000 Dec; 113(12):1068-70. PubMed ID: 11776137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging.
    Vlassara H; Bucala R; Striker L
    Lab Invest; 1994 Feb; 70(2):138-51. PubMed ID: 8139257
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.